Analysis reveals big costs savings for DHA supplements during pregnancy

By Stephen Daniells contact

- Last updated on GMT

Image: iStockPhoto
Image: iStockPhoto

Related tags: Omega-3 fatty acid

Supplementing pregnant mothers with DHA omega-3 could lead to significant costs savings for patients and healthcare systems, according to a new analysis from Australia.

Data from the "DHA to Optimize Mother and Infant Outcome" (DOMInO) trial indicated that DHA supplementation was associated with 15% lower rates of pre-term births, and this could result in significant in-patient hospital cost savings.

A regression analysis by Professor Maria Makrides’ group at Adelaide University showed that DHA supplementation may generate annual costs savings to the Australian public hospital system of AUS$15-51 million (US$11-37 million).

“There is now an ongoing debate on whether the consumption of adequate amounts of omega-3 fatty acids, especially DHA, during pregnancy and breastfeeding, is associated with improvements in maternal and infant health,”​ wrote the researchers in Prostaglandins, Leukotrienes and Essential Fatty Acids​.

“Given that the cost of the fish oil supplement is small, if relatively simple interventions like DHA-rich fish-oil supplementation during pregnancy can generate cost savings from a public policy perspective, it may be worthwhile considering implementing programs that encourage DHA supplementation among pregnant women.”

Analysis details

The DOMInO trial involved 2,399 women pregnant with only one baby at less than 20 weeks gestation. The women were randomly assigned to receive DHA-rich fish oil capsules (800 mg/d of DHA) or matched vegetable oil capsules without DHA until the birth of their children.

The study found that the number of early pre-term birth cases was reduced by 15% for the DHA group compared to the control group, and that DHA supplementation provided a 50% chance of avoiding an additional premature birth.

The new econometric analysis found that DHA supplements during pregnancy may decrease in-patient hospital costs by an average of AU$92 (US$67) for singleton pregnancies. For 163,500 singleton pregnancies per year, this would extrapolate to a total potential cost savings to the Australian public hospital system of AUS$15-51 million per year (US$11-37 million per year).

Longer term benefits

Omega-3 Softgels © mphillips007
Image © iStockPhoto / mphillips007

The researchers noted that they did not factor in the longer term benefits of DHA supplementation during pregnancy for healthcare or social costs.

“The study found that there was a 15% reduction in early pre-term birth through DHA supplementation during pregnancy. Given that pre-term births could have long term complications, this study may understate the actual cost effectiveness of DHA supplementation,”​ they wrote.

“Additionally, the DOMInO trial sample only included patients that attended public hospitals and therefore, as a robustness check, it would be useful to expand this study to private hospital patients as well.

“Lastly, although there is a general consensus that DHA contributes to improved pregnancy and birth outcomes, there is a lack of agreement on the optimal dose of DHA supplementation. The benefits observed here relate to dose used in the DOMInO trial and further studies will need to determine if similar cost savings can be achieved with other doses.

“Policy makers will ultimately need to quantify the cost of providing or subsidizing DHA supplements for women separately or together with other supplements, such as folic acid, relative to the savings and improved pregnancy and birth outcomes that potentially result from such supplementation.”

The paper’s authors were affiliated with the Women’s and Children’s Health Research Institute (North Adelaide), the South Australian Health and Medical Research Institute (Adelaide), the University of Adelaide, the Women's and Children's Health Network, and Joondalup Health Campus (Perth).

Source: Prostaglandins, Leukotrienes and Essential Fatty Acids
Volume 102-103, Pages 5-11, doi: 10.1016/j.plefa.2015.08.002
“Analysis of hospital cost outcome of DHA-rich fish-oil supplementation in pregnancy: Evidence from a randomized controlled trial”
Authors: S. Ahmed, et al. 

Related news

Show more

Related products

show more

LIPOFER™- Bioavailable and stable iron source

LIPOFER™- Bioavailable and stable iron source

Lipofoods, a Lubrizol Company | 29-Jul-2020 | Product Brochure

Iron fortification is generally considered the best approach to prevent iron deficiency. However, the chemical reactivity of iron species often results...

DHA ORIGINS™: The sustainable potential of algae.

DHA ORIGINS™: The sustainable potential of algae.

Fermentalg | 22-Jun-2020 | Technical / White Paper

Consumers find out about nutritional quality by closely scrutinizing the labeling and list of ingredients (clean label). They are interested in the provenance...

EXPERT’Biotics for babies

EXPERT’Biotics for babies

Lallemand Health Solutions | 16-Mar-2020 | Technical / White Paper

Lallemand Health Solutions (LHS) has a large portfolio of EXPERT’Biotics solutions, including Lacidofil®, Probiokid®, Lafti B94®, S. boulardii, L. rhamnosus...

HRB are ideal probiotics for human health

HRB are ideal probiotics for human health

Morinaga Milk Industry Co., Ltd. | 20-Nov-2019 | Technical / White Paper

Evidence is accumulated that the physiological benefits of probiotics bifidobacteria are not only strain-specific but also dependent on their residential...

Related suppliers

Follow us

Products

View more

Webinars